The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zealand Pharma A/S
CSE:ZEAL
|
DK |
|
O
|
Origin Energy Ltd
OTC:OGFGF
|
AU |
|
V
|
Verizon Communications Inc
DUS:BAC
|
US |
|
P
|
Prudential Financial Inc
F:PLL
|
US |
|
T
|
Tetra Tech Inc
SWB:TT6
|
US |
|
SEB SA
PAR:SK
|
FR |
|
Nanobiotix SA
PAR:NANO
|
FR |
|
M
|
Mediobanca Banca di Credito Finanziario SpA
DUS:ME9
|
IT |
|
National Australia Bank Ltd
ASX:NAB
|
AU |
|
Nanobiotix SA
LSE:0QAV
|
FR |
|
Temple & Webster Group Ltd
ASX:TPW
|
AU |
|
J Sainsbury PLC
LSE:SBRY
|
UK |
|
O
|
OMV AG
SWB:OMV
|
AT |
|
N
|
National Australia Bank Ltd
OTC:NAUBF
|
AU |
|
C
|
CRH PLC
XHAM:CRG
|
IE |
|
A
|
AMC Global Media Inc
SWB:9AC
|
US |
|
Harmony Gold Mining Company Ltd
NYSE:HMY
|
ZA |
|
H
|
Harmony Gold Mining Company Ltd
JSE:HAR
|
ZA |
|
A
|
Amgen Inc
XHAN:AMG
|
US |
|
J
|
J Sainsbury PLC
DUS:SUY1
|
UK |
|
G
|
G8 Education Ltd
F:3EAG
|
AU |
|
Temple & Webster Group Ltd
F:2Q9
|
AU |
|
F
|
Fujifilm Holdings Corp
DUS:FJI
|
JP |
|
SGS SA
OTC:SGSOF
|
CH |
Zealand Pharma A/S (ZEAL)’s 12-month stock price forecast through November 2027 has a consensus target of kr382.5, implying 66% upside. The forecast is based on price targets from 17 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for
ZEAL is 382.5 DKK with a low forecast of 292.9 DKK and a high forecast of 787.5 DKK.
Over the last 13 years, the compound annual growth rate for Revenue has been 33%. The projected CAGR for the next 8 years is -7%.
The compound annual growth rate for Gross Profit over the next 3 years is -64%.
Over the last 13 years, the compound annual growth rate for Operating Income has been 51%. The projected CAGR for the next 8 years is -18%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more